drugset / Trial / NCT05625633
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Phase 2/3
Recruiting
120 enrolled
Western Institute for Veterans Research
Merck Sharp & Dohme LLC · collabUniversity of Utah · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Timeline
- Start
- 2024-03-25
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil 9 | Vaccine | 0.5 ml | Intramuscular |